Chain vertical integration?
Executive Summary
With ANDA bill under serious consideration to allow easier access to generic approvals for the Rx drugs first approved in the U.S. between the years 1962-1981, a logical step for the next wave of chain drug acquisitions may be generic drug producers. Some observers estimate that 125 Rx drugs will be available for generic approvals from FDA if the bill is passed. That quantity for drugs should make vertical integration into production more attractive to chains. Some, such as Revco, already have a head start in that area.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.